This page collects WhisperX intelligence signals tagged #Biogen. It is designed for humans, search engines, and AI agents: each item links to a canonical source-backed record with sector, source, timestamp, credibility, and exportable structured data.
A joint congressional investigation has exposed unprecedented collusion between the FDA and Biogen to push through the controversial Alzheimer's drug Aduhelm. Internal communications and whistleblower testimonies reveal that FDA officials and Biogen executives engaged in dozens of undocumented "off-the-books" meetings,...
Investment firm Piper Sandler has upgraded Biogen's stock rating to Overweight, a move directly tied to the potential acquisition of Apellis Pharmaceuticals. This analyst action signals a significant shift in sentiment, placing a high-stakes strategic bet on Biogen's future direction. The upgrade is not based on curren...